{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:39:49Z","timestamp":1786981189735,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10787-024-01436-9","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T12:02:19Z","timestamp":1707393739000},"page":"991-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-8039","authenticated-orcid":false,"given":"Mohammad Ali","family":"Nilforoushzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-4066","authenticated-orcid":false,"given":"Yekta","family":"Ghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-8814","authenticated-orcid":false,"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-5631","authenticated-orcid":false,"given":"Arman","family":"Hajikarim-Hamedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-2270","authenticated-orcid":false,"given":"SeyedAyin","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9378-9738","authenticated-orcid":false,"given":"Fariba","family":"Jaffary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3010-3543","authenticated-orcid":false,"given":"Minou","family":"Najar Nobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1320-7673","authenticated-orcid":false,"given":"Pegah","family":"Tavakolzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-1980","authenticated-orcid":false,"given":"Niloufar","family":"Najar Nobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"issue":"3","key":"1436_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2340\/00015555-2232","volume":"96","author":"S Bobko","year":"2016","unstructured":"Bobko S, Zeidler C, Osada N, Riepe C, Pfleiderer B, Pogatzki-Zahn E et al (2016) Intraepidermal nerve fibre density is decreased in lesional and inter-lesional prurigo nodularis and reconstitutes on healing of lesions. Acta Derm Venereol 96(3):404\u2013406. https:\/\/doi.org\/10.2340\/00015555-2232","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1436_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","volume":"79","author":"E Boozalis","year":"2018","unstructured":"Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S et al (2018) Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 79(4):714\u20139.e3. https:\/\/doi.org\/10.1016\/j.jaad.2018.04.047","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1436_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","volume":"133","author":"F Cevikbas","year":"2014","unstructured":"Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A et al (2014) A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 133(2):448\u2013460. https:\/\/doi.org\/10.1016\/j.jaci.2013.10.048","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1436_CR4","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/all.14791","volume":"76","author":"A Datsi","year":"2021","unstructured":"Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J (2021) Interleukin-31: the \u201citchy\u201d cytokine in inflammation and therapy. Allergy 76(10):2982\u20132997. https:\/\/doi.org\/10.1111\/all.14791","journal-title":"Allergy"},{"key":"1436_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2609","author":"J Deng","year":"2023","unstructured":"Deng J, Liao V, Parthasarathy V, Cornman HL, Kambala A, Kwatra MM et al (2023) Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2609","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1436_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/all.13239","volume":"73","author":"M Furue","year":"2018","unstructured":"Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y (2018) Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 73(1):29\u201336. https:\/\/doi.org\/10.1111\/all.13239","journal-title":"Allergy"},{"issue":"6","key":"1436_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM et al (2021) Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol 30(6):804\u2013810. https:\/\/doi.org\/10.1111\/exd.14279","journal-title":"Exp Dermatol"},{"issue":"5","key":"1436_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cytogfr.2015.07.006","volume":"26","author":"HM Hermanns","year":"2015","unstructured":"Hermanns HM (2015) Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev 26(5):545\u2013558. https:\/\/doi.org\/10.1016\/j.cytogfr.2015.07.006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"1436_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang AH, Williams KA, Kwatra SG (2020) Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol 83(6):1559\u20131565. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.183","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1436_CR10","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.13827","volume":"31","author":"KM J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP (2017) Anxiety, depression and suicide in patients with prurigo nodularis. J Eur Acad Dermatol Venereol 31(2):e106\u2013e107. https:\/\/doi.org\/10.1111\/jdv.13827","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1436_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2608","author":"SW Kashem","year":"2023","unstructured":"Kashem SW, Fassett MS (2023) Can Serum biomarkers for prurigo nodularis expose pathophysiology or just treatment response? JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2608","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1436_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMe1916733","volume":"382","author":"SG Kwatra","year":"2020","unstructured":"Kwatra SG (2020) Breaking the itch-scratch cycle in prurigo nodularis. N Engl J Med 382(8):757\u2013758. https:\/\/doi.org\/10.1056\/NEJMe1916733","journal-title":"N Engl J Med"},{"issue":"17","key":"1436_CR13","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D et al (2023) Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 389(17):1579\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"1436_CR14","unstructured":"L. National Heart aBI. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014."},{"issue":"4","key":"1436_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1440-0960.2005.00187.x","volume":"46","author":"MR Lee","year":"2005","unstructured":"Lee MR, Shumack S (2005) Prurigo nodularis: a review. Australas J Dermatol 46(4):211\u2013218. https:\/\/doi.org\/10.1111\/j.1440-0960.2005.00187.x","journal-title":"Australas J Dermatol"},{"issue":"7","key":"1436_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1034\/j.1600-0560.2000.027007359.x","volume":"27","author":"Y Liang","year":"2000","unstructured":"Liang Y, Jacobi HH, Reimert CM, Haak-Frendscho M, Marcusson JA, Johansson O (2000) CGRP-immunoreactive nerves in prurigo nodularis\u2013an exploration of neurogenic inflammation. J Cutan Pathol 27(7):359\u2013366. https:\/\/doi.org\/10.1034\/j.1600-0560.2000.027007359.x","journal-title":"J Cutan Pathol"},{"key":"1436_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825312","author":"J Liang","year":"2022","unstructured":"Liang J, Hu F, Dan M, Sang Y, Abulikemu K, Wang Q et al (2022) Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.825312","journal-title":"Front Immunol"},{"key":"1436_CR18","doi-asserted-by":"publisher","unstructured":"McCampbell LE, Zaino ML, Ranpariya M, Patel T, Feldman SR (2023) Systemic medication for the treatment of prurigo nodularis-a systematic review. J Cutan Med Surg 27(6):641\u2013645. https:\/\/doi.org\/10.1177\/12034754231211797. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools","DOI":"10.1177\/12034754231211797"},{"key":"1436_CR19","doi-asserted-by":"publisher","unstructured":"Mikhak Z, St\u00e4nder S, Metze D, Yosipovitch G, Silverberg J, Gandhi R et al (2019a) 202 The oncostatin M receptor beta axis identified in prurigo nodularis. J Investig Dermatol 139(5):S35\u2013S35. https:\/\/doi.org\/10.1016\/j.jid.2019.03.278. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools","DOI":"10.1016\/j.jid.2019.03.278"},{"key":"1436_CR20","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.jid.2019.03.636","volume":"139","author":"Z Mikhak","year":"2019","unstructured":"Mikhak Z, Bissonnette R, Siri D, Tyring SK, Tessari E, Gandhi R et al (2019b) 560 KPL-716, anti-oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis. J Investig Dermatol 139:S96. https:\/\/doi.org\/10.1016\/j.jid.2019.03.636","journal-title":"J Investig Dermatol"},{"issue":"4","key":"1436_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.21698","volume":"187","author":"L Misery","year":"2022","unstructured":"Misery L (2022) Chronic prurigo. Br J Dermatol 187(4):464\u2013471. https:\/\/doi.org\/10.1111\/bjd.21698","journal-title":"Br J Dermatol"},{"issue":"3","key":"1436_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","volume":"51","author":"NK Mollanazar","year":"2016","unstructured":"Mollanazar NK, Smith PK, Yosipovitch G (2016) Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol 51(3):263\u2013292. https:\/\/doi.org\/10.1007\/s12016-015-8488-5","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"1436_CR23","doi-asserted-by":"publisher","first-page":"100233","DOI":"10.1016\/j.xjidi.2023.100233","volume":"3","author":"CL Morgan","year":"2023","unstructured":"Morgan CL, Thomas M, Heywood BR, St\u00e4nder S, Kwatra SG, Jabbar-Lopez ZK et al (2023) incident comorbidity, resource use, and all-cause mortality associated with prurigo nodularis: a united kingdom retrospective database analysis. JID Innov 3(6):100233. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100233","journal-title":"JID Innov"},{"key":"1436_CR24","unstructured":"National Heart L, and Blood Institute. Quality Assessment of Clinical trials. 2014."},{"key":"1436_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"2","key":"1436_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","volume":"122","author":"U Raap","year":"2008","unstructured":"Raap U, Wichmann K, Bruder M, St\u00e4nder S, Wedi B, Kapp A et al (2008) Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122(2):421\u2013423. https:\/\/doi.org\/10.1016\/j.jaci.2008.05.047","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"1436_CR27","doi-asserted-by":"publisher","first-page":"adv00197","DOI":"10.2340\/00015555-3505","volume":"100","author":"CD Richards","year":"2020","unstructured":"Richards CD, Gandhi R, Botelho F, Ho L, Paolini JF (2020) Oncostatin M induction of monocyte chemoattractant protein 1 is inhibited by anti-oncostatin M receptor beta monoclonal antibody KPL-716. Acta Derm Venereol 100(14):adv00197. https:\/\/doi.org\/10.2340\/00015555-3505","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1436_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamadermatol.2023.3251","volume":"159","author":"D Rodriguez","year":"2023","unstructured":"Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Jabbar Lopez ZK, Piketty C et al (2023) patient perspectives on living with severe prurigo nodularis. JAMA Dermatol 159(11):1205\u20131212. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3251","journal-title":"JAMA Dermatol"},{"key":"1436_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101826","author":"H Sofen","year":"2023","unstructured":"Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ et al (2023) Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. Eclinicalmedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101826","journal-title":"Eclinicalmedicine"},{"issue":"2","key":"1436_CR30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2019.07.022","volume":"82","author":"HF St\u00e4nder","year":"2020","unstructured":"St\u00e4nder HF, Elmariah S, Zeidler C, Spellman M, St\u00e4nder S (2020a) Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol 82(2):460\u2013468. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.022","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1436_CR31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, Lacour J, Paul C, Narbutt J et al (2020b) Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 382(8):706\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa1908316","journal-title":"N Engl J Med"},{"issue":"10","key":"1436_CR32","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/jdv.18377","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A et al (2022) Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol 36(10):1820\u20131825. https:\/\/doi.org\/10.1111\/jdv.18377","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1436_CR33","doi-asserted-by":"publisher","first-page":"B27","DOI":"10.1016\/j.jid.2021.07.078","volume":"141","author":"L Tsoi","year":"2021","unstructured":"Tsoi L, Fogel P, Xing X, Patrick MT, Billi AC, Berthier CC et al (2021) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Investig Dermatol 141(9):B27","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1436_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","volume":"14","author":"KA Williams","year":"2021","unstructured":"Williams KA, Roh YS, Brown I, Sutaria N, Bakhshi P, Choi J et al (2021) Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol 14(1):67\u201377. https:\/\/doi.org\/10.1080\/17512433.2021.1852080","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"1436_CR35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jaad.2019.02.061","volume":"82","author":"G Yosipovitch","year":"2020","unstructured":"Yosipovitch G (2020) Prurigo nodularis: new treatments on the horizon. J Am Acad Dermatol 82(4):1035\u20131036. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.061","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1436_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-2774","volume":"98","author":"C Zeidler","year":"2018","unstructured":"Zeidler C, Tsianakas A, Pereira M, St\u00e4nder H, Yosipovitch G, St\u00e4nder S (2018) Chronic prurigo of nodular type: a review. Acta Derm Venereol 98(2):173\u2013179. https:\/\/doi.org\/10.2340\/00015555-2774","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1436_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2340\/00015555-3150","volume":"99","author":"W Zhong","year":"2019","unstructured":"Zhong W, Wu X, Zhang W, Zhang J, Chen X, Chen S et al (2019) Aberrant expression of histamine-independent pruritogenic mediators in keratinocytes may be involved in the pathogenesis of prurigo nodularis. Acta Derm Venereol 99(6):579\u2013586. https:\/\/doi.org\/10.2340\/00015555-3150","journal-title":"Acta Derm Venereol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01436-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T09:31:44Z","timestamp":1712741504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01436-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01436-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"1 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}}]}}